Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset

NEXT STORY
Antares Pharma to Present at the Ladenburg Thalmann Annual Healthcare Conference
PREV STORY
Finn Partners Acquires Leading Health Technology Communications Firm Agency Ten22
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Orion Group Financial Statement documents 2017 and Corporate Governance Statement published

ORION CORPORATION           STOCK EXCHANGE RELEASE         26 FEBRUARY 2018 at 13.00 EET                       Orion Group ...

author_avatar
NASDAQ Market News

BioSig Technologies Issues Shareholder Letter

Minneapolis, MN, July 19, 2016 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device ...

author_avatar
NASDAQ Market News

OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®

Trial in Non-Small Cell Lung Cancer (NSCLC) Patients After Immune Checkpoint Inhibitor FailureCheckpoint Inhibitor ...

author_avatar
NASDAQ Market News